Compare Ascendis Pharma A/S (ASND) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Expeditors International of Wshngtn Inc — how do they compare? Ascendis Pharma A/S trades at $253.57 (market cap $16.67B), while Expeditors International of Wshngtn Inc trades at $180.11 (market cap $23.04B). The key difference: Expeditors International of Wshngtn Inc is the larger of the two by market cap, and Expeditors International of Wshngtn Inc pays a 0.91% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EXPD | |
|---|---|---|
Market Cap | $16.67B | $23.04B |
Sector | Health | Industrials |
52-Week High | $277.18 | $182.80 |
52-Week Low | $189.74 | $113.13 |
Enterprise Value | $17.04B | $22.57B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
EXPD trades at $179.00, near its 52-week high, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings of $2.03 per share, beating estimates by 20%, driven by airfreight and customs demand. Revenue growth is steady, with 2026 projected at $12.0B, though ocean freight contraction poses a headwind. Analyst consensus is a Hold with a $181.14 price target, indicating limited near-term upside.
Outlook: EXPD's earnings momentum and expanding AOG services offer growth potential, but high valuation (P/E 25.79) and reliance on tariff policies heighten risk. Investors should weigh robust profitability (ROE 42.6%) against cyclical freight pressures and analyst caution. The stock is fairly valued, with gains contingent on sustaining airfreight strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
